An AI-Based OCT System to Detect Diabetic Macular Edema
JAMA · 21.07.2026 · 336 (3) · 215
DOI: 10.1001/jama.2026.7025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 21.07.2026. Verfasst von Shuyi Zhang und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR), China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Macular Edema, Tomography, Optical Coherence, Artificial Intelligence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Screening for diabetic retinopathy using fundus photographs is the global standard of care but results in high false-positive referrals to evaluate diabetic macular edema (DME), placing a substantial burden on specialist eye clinics. Integrating an AI-based optical coherence tomography (AI-OCT) system into screening pathways may reduce potentially unnecessary referrals.
Objective
To evaluate the diagnostic and referral performance of an AI-OCT system for DME detection within a diabetic retinopathy screening pathway in clinical settings. Design, Setting, and Participants Stepwise evaluation conducted in Hong Kong Special Administrative Region: a prospective silent-mode validation (February 2020 to July 2023) recruiting 603 patients with diabetes at a tertiary hospital triage unit, followed by a multicenter noninferiority RCT (September 2023 to April 2025), with follow-up completed in May 2025, recruiting 276 patients with suspected DME referred from a territory-wide diabetic retinopathy screening program.
Interventions
RCT participants were randomized to intervention (referral for DME evaluation based on both fundus photograph–based screening reports and AI-OCT reports [n = 137]) or control (automatic referral based solely on fundus photograph–based screening reports [n = 139]) groups. The AI-OCT system incorporated image-quality assessment, DME detection, and uncertainty flagging. Study outcomes focused on referral rates under the 2 pathways; for ethical reasons, all participants ultimately underwent specialist evaluation. Main Outcomes and Measures The primary outcome was false-positive DME referral rate, with a prespecified noninferiority margin of 20%. The secondary outcomes included sensitivity and specificity for DME detection and DME referral.
Results
In prospective silent-mode validation (mean age, 64.7 [SD, 9.4] years; 56.2% male), 86 of 1200 scans (7.2%) were identified as ungradable and 49 of 1114 gradable scans (4.4%) were classified as uncertain. The system achieved 98.8% (95% CI, 94.5%-100.0%) sensitivity and 90.7% (95% CI, 88.7%-92.4%) specificity for DME detection. In the RCT (mean age, 63.9 [SD, 10.9] years; 54.7% male), DME prevalence was similar in the intervention and control groups (30.9% vs 29.9%). The false-positive DME referral rate was 24.1% (95% CI, 14.6%-37.0%) and 69.1% (95% CI, 61.0%-76.1%), respectively (absolute difference, −45% [95% CI, −58.2% to −31.9%; P < .001 for noninferiority]; upper bound of the CI below the prespecified noninferiority margin of 20%). Sensitivity for DME referral was 100.0% (95% CI, 100.0%-100.0%) in both groups. Specificity for DME referral was 86.5% (95% CI, 79.3%-92.9%) in the intervention group and 0.0% (95% CI, 0.0%-0.0%) in the control group. No cases of DME occurred among nonreferred participants in the intervention group. Conclusions and Relevance Compared with standard practice, incorporation of the AI-OCT system as a secondary screening tool was noninferior with respect to false-positive referral rates and was associated with a substantial reduction in potentially unnecessary DME referrals without compromising sensitivity. Trial Registration Chinese Clinical Trial Registry: ChiCTR2300075087
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.
- Hong Kong Eye Hospital, Hong Kong SAR, China.
- Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong SAR, China.
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
- United Christian Hospital, Hong Kong SAR, China.
- Tseung Kwan O Hospital, Hong Kong SAR, China.
Zitieren
APA
Zhang, S., Ran, A., Zhou, J., Ling, A., Sham, K., Zhang, Y., Tang, Z., Nguyen, T. X., Yang, D., Lam, N., Yuen, H. K. L., Chan, V. T. T., Ho, M., Chan, J. Y. Y., Lam, T. C. H., Yim, C. C. L., Chow, C. W. Y., Cheung, S. S. L., Lam, M. C. W., …, & Cheung, C. Y. (2026). An AI-Based OCT System to Detect Diabetic Macular Edema. JAMA. https://doi.org/10.1001/jama.2026.7025
Vancouver
Zhang S, Ran A, Zhou J, Ling A, Sham K, Zhang Y, et al. An AI-Based OCT System to Detect Diabetic Macular Edema. JAMA. 2026. doi:10.1001/jama.2026.7025
BibTeX
@article{Zhang2026,
author = {Zhang, Shuyi and Ran, Anran and Zhou, Jiaying and Ling, Anni and Sham, Kaiser and Zhang, Yu and Tang, Ziqi and Nguyen, Truong X and Yang, Dawei and Lam, Naiman and Yuen, Hunter K L and Chan, Victor T T and Ho, Mary and Chan, Julia Y Y and Lam, Thomas C H and Yim, Charlene C L and Chow, Claire W Y and Cheung, Stephanie S L and Lam, Matthew C W and Lai, Anthony C H and Wong, Cherie Y K and Yu, Amy H Y and Hui, Vivian W K and Mak, Andrew C Y and Li, Sophia Ling and Chan, Noel C Y and Yip, Wilson W K and Young, Alvin L and Ozaki, Risa and Loo, Kit-Man and Luk, Andrea O Y and Chan, Juliana C N and Chan, Pangfai and Luk, Matthew M H and Lai, Loretta K P and Wong, Daniel H T and Shiu, Jasmine and Wang, Xi and Heng, Pheng-Ann and Lin, Haotian and Sivaprasad, Sobha and Wong, Tien Yin and Li, Kenneth K W and Chan, Carmen K M and Pang, Chi Pui and Tham, Clement C and Lai, Timothy Y Y and Szeto, Simon K H and Cheung, Carol Y},
title = {An AI-Based OCT System to Detect Diabetic Macular Edema},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.7025}
}
EUVIMED